Fidaxomicin: a new option for the treatment of Clostridium difficile infection

Decreased Cure and Increased Recurrence Rates for Clostridium difficile Infection Caused by the Epidemic C. difficile BI Strain

(2012) Laurica A. Petrella et al.   CLINICAL INFECTIOUS DISEASES

Clinical and economic burden of Clostridium difficile infection in Europe: a systematic review of healthcare-facility-acquired infection

(2012) P.N. Wiegand et al.   JOURNAL OF HOSPITAL INFECTION

Fidaxomicin versus vancomycin for infection with Clostridium difficile in Europe, Canada, and the USA: a double-blind, non-inferiority, randomised controlled trial

(2012) Oliver A Cornely et al.   LANCET INFECTIOUS DISEASES

Comparative Susceptibilities to Fidaxomicin (OPT-80) of Isolates Collected at Baseline, Recurrence, and Failure from Patients in Two Phase III Trials of Fidaxomicin against Clostridium difficile Infection

(2011) Ellie J. C. Goldstein et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Efficacy of Fidaxomicin Versus Vancomycin as Therapy for Clostridium difficile Infection in Individuals Taking Concomitant Antibiotics for Other Concurrent Infections

(2011) Kathleen M. Mullane et al.   CLINICAL INFECTIOUS DISEASES

Fidaxomicin: first-in-class macrocyclic antibiotic

(2011) Kathleen M Mullane et al.   Expert Review of Anti-Infective Therapy

Fidaxomicin versus Vancomycin forClostridium difficileInfection

(2011) Thomas J. Louie et al.   NEW ENGLAND JOURNAL OF MEDICINE

The Changing Epidemiology of Clostridium difficile Infections

(2010) J. Freeman et al.   CLINICAL MICROBIOLOGY REVIEWS

A new macrocyclic antibiotic, fidaxomicin (OPT-80), causes less alteration to the bowel microbiota of Clostridium difficile-infected patients than does vancomycin

(2010) G. W. Tannock et al.   MICROBIOLOGY-SGM

Typing and susceptibility of bacterial isolates from the fidaxomicin (OPT-80) phase II study for C. difficile infection

(2009) D.M. Citron et al.   ANAEROBE

Recurrent Clostridium difficile infection: A review of risk factors, treatments, and outcomes

(2009) Stuart Johnson   JOURNAL OF INFECTION

In Vitro Activity of OPT-80 Tested against Clinical Isolates of Toxin-Producing Clostridium difficile

(2008) J. A. Karlowsky et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Safety, Tolerance, and Pharmacokinetic Studies of OPT-80 in Healthy Volunteers following Single and Multiple Oral Doses

(2008) Y. K. Shue et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Clinical Outcomes, Safety, and Pharmacokinetics of OPT-80 in a Phase 2 Trial with Patients with Clostridium difficile Infection

(2008) T. Louie et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

OPT-80 Eliminates Clostridium difficile and Is Sparing of Bacteroides Species during Treatment of C. difficile Infection

(2008) T. J. Louie et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Editorial Commentary:Decreased Effectiveness of Metronidazole for the Treatment ofClostridium difficileInfection?

(2008) Ed J. Kuijper et al.   CLINICAL INFECTIOUS DISEASES

Prospective Derivation and Validation of a Clinical Prediction Rule for Recurrent Clostridium difficile Infection

(2008) Mary Y. Hu et al.   GASTROENTEROLOGY

Review of Current Literature on the Economic Burden of Clostridium difficile Infection

(2008) Erik R. Dubberke et al.   INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY

Emergence of reduced susceptibility to metronidazole in Clostridium difficile

(2008) S. D. Baines et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY